lncRNA‑CD160 decreases the immunity of CD8+ T cells through epigenetic mechanisms in hepatitis B virus infection

Abstract

The transfer and development of chronic hepatitis B virus (HBV) infection is associated with the T cell immune response, therefore investigating the key regulators of cell immune response is needed to improve chronic HBV treatment. Blood samples from patients with chronic HBV infection were used to confirm the correlation between HBV infection stage and CD160 receptor expression levels in CD8 + T cells, the CD8 + T cells are used to research the mechanism of T cell immune response modulation, moreover, C3H/HeN mice with reduced CD160 expression levels were used to investigate the association between long non-coding (lnc)RNA-CD160 and HBV infection. Long non-coding (lnc)RNA-CD160 and histone-modification enzyme gene histone deacetylase 11 (HDAC11) expression levels were negatively associated with CD160 expression. lncRNA-CD160 can inhibit the secretion of IFN-γ and TNF-α through HDAC11 recruitment and bind to HDAC11 to form a complex on the promoters of IFN-γ and TNF-α. The HDAC11, IFN-γ and TNF-α form a complex and enhance the methylation of H3K9Me1, chromatin changes into the heterochromatin and the transcription of IFN-γ and TNF-α is blocked; moreover, the HDAC11/IFN-γ/TNF-α complex can also inhibit the secretion of IFN-γ and TNF-α in CD160 -CD8 + T cells and suppresses the function of CD8 + T cells. Furthermore, small interfering RNA targeting lncRNA-CD160 can block HBV infection progression. lncRNA-CD160 acts as an immune suppressive factor and is expressed at a high level in peripheral blood CD8 + T cells of HBV infected patients. Furthermore, high expression levels of lncRNA-CD160 can contribute to the inhibition of IFN-γ and TNF-α secretion in CD8 + T cells and decrease the immune response of CD8 + T cells. Therefore, lncRNA-CD160 may become a new target for immunotherapy of chronic HBV infection in the future and may provide a new therapeutic strategy for the treatment of HBV infection.

Changes in gene expression at the CD160 locus in the whole blood of sepsis patients.

“…There is limited published information on non-coding RNAs produced at the CD160 locus. One recently published study suggested that a non-coding RNA produced at the CD160 locus, termed lncRNA-CD160 functioned in an immunosuppressive manner in CD8+ T-cells of patients infected with hepatitis B virus 15 . However, it is unclear exactly which transcript this corresponds to with respect to the transcripts we identified here as differentially expressed in patients with sepsis, as we detect at least two unique CD160 long non-coding RNA transcripts induced in the whole blood during sepsis.…”

Long noncoding RNAs in hepatitis B virus replication and oncogenesis

“…Thus, lncRNA-CD160 acts as an immune suppressor. Indeed, knockdown of lncRNA-CD160 can block HBV infection[ 23 ].…”

Potential impact and mechanism of Long Non-coding RNAs on cancer and associated T cells

“…Yang Wang et al showed that lncRNA-CD244 which is induced by CD244 + CD8 + T cell in active tuberculosis (TB) infection inhibits IFN-γ/TNF-α expression in CD8 + T cells through recruitment of EZH2 to IFNG and TNFA loci for repressive chromatin states [58]. Moreover, Jiansong Wu et al have found that lncRNA-CD160 bind to histone-modification enzyme gene histone deacetylases 11 (HDAC11) to form a complex and inhibit the function of HDAC11, which further inhibits the secretion of IFN-γ and TNF-α in in hepatitis B virus infection [59].…”